Loading viewer...
earnings
Format: PDF earnings
Ascelia Pharma presented its H1 2024 results highlighting the successful completion of Phase 3 clinical development for Orviglance®. The presentation covers quarterly financial performance, recent milestones, and the company's pipeline strategy in orphan oncology focused on delivering targeted cancer treatments.
earnings
75 Pages
Macquarie Group
Brookfield Asset Management 2016 Earnings Presentation
earningsearnings
37 Pages
Brookfield Asset Management
Litigation Capital Management 2022 Full Year Results
earningsearnings
29 Pages
Litigation Capital Management Limited